Table 1.
Baseline characteristics of trials included in meta-analysis. CANA canagliflozin, DAPA dapagliflozin, EMPA empagliflozin, PBO placebo, left ventricular ejection LVEF, age and LVEF were reported in Mean, * for median(Q1,Q3), NR, not reported
| T2D,n (%) | 166(63.1) | 1466(58.9) | 1856(49.8) | 0(0) | 2806(44.8) | 25(13.1) | 125(27.9) | 634(52.3) | 84(80) |
| LVEF, % | 26.4(8.1) | 54.3(8.8) | 27.4(6.1) | 36.3(8.1) | 54.2(8.8) | 29.5(8.0) | NR | 43.7(16.2) | 32.5(9.8) |
| Male, n (%) | 193(73.4) | 3312(55.3) | 2837(76.1) | 54(64.3) | 3516(56.1) | 162(85.3) | 251(55.2) | 11(63.1) | 77(73.3) |
| Age,years | 61.3(11.5) | 71.9(9.4) | 66.8(11.0) | 62(12.1) | 71.7(9.6) | 64(8.5) | 63.4(13.3) | 66.2(12.9) | 68.7(11.1) |
| Interventions | DAPA 10 mg, PBO | EMPA 10 mg, PBO | EMPA 10 mg, PBO | EMPA 10 mg, PBO | DAPA 10 mg, PBO | EMPA 10 mg, PBO | CANA 100 mg, PBO | EMPA 10 mg, PBO | EMPA 10 mg, PBO |
| Participants,n | 263 | 4988 | 3730 | 84 | 6263 | 190 | 448 | 65 | 105 |
| Follow-up,weeks | 52 | 52 | 148 | 26 | 169 | 12 | 12 | 12 | 36 |
| Condition | HFrEF | HFpEF | HFrEF | HFrEF | HFpEF | HFrEF | HF | HF | HFrEF |
| Country | United States | United States | United States | United States | United States | Denmark | United States | United States | United Kingdom |
| Completion Date | 2019/6/28 | 2021/4/26 | 2020/5/28 | 2020/2/13 | 2022/3/27 | 2020/1/17 | 2021/11/09 | 2020/03/10 | 2020/03/18 |
| NCT ID | NCT02653482 | NCT03057951 | NCT03057977 | NCT03485222 | NCT03619213 | NCT03198585 | NCT04252287 | NCT03030222 | NCT03485092 |
| Study | DEFINE-HF [19, 20] | EMPEROR-Preserved [21–23] | EMPEROR-Reduced [8, 24, 25] |
EMPA-TROPIS |
DELIVER [28, 29] | Empire HF [30, 31] | CHIEF-HF [32, 33] | EMBRACE-HF [34] | SUGAR-DM-HF [35] |
| T2D,n (%) | 1983(41.8) | 181(55.9) | NR | NR | NR | NR | 73(49.7) | 50(100) | 29(25.9) |
| LVEF, % | 31.1(6.8) | 60(54, 65)* | NR | NR | NR | NR | 28.3(7.2) | 47.3(9.1) | 45.5(3.3) |
| Male, n (%) | 3635(76.6) | 140(43.2) | 232(74.4) | 179(56.8) | 233(74.4) | 320(63.5) | 112(76.2) | 28(56) | 84(75) |
| Age,years | 66.3(10.9) | 70(63, 77)* | 69.0(10.2) | 73.5(8.8) | 67.8(10.4) | 71.8(9.4) | 61.9(11.6) | 66.1(7.1) | 69(57,78)* |
| Interventions | DAPA 10 mg, PBO | DAPA 10 mg, PBO | EMPA 10 mg, PBO | EMPA 10 mg, PBO | DAPA 10 mg, PBO | DAPA 10 mg, PBO | DAPA 10 mg, PBO |
DAPA 10 mg,CA NA 100 mg, PBO |
EMPA 10 mg, PBO |
| Participants,n | 4744 | 324 | 312 | 313 | 313 | 504 | 147 | 50 | 112 |
| Follow-up,weeks | 104 | 12 | 12 | 12 | 16 | 16 | 52 | 26 | 83 |
| Condition | HFrEF | HFpEF | HFrEF | HFpEF | HFrEF | HFpEF | HFrEF | HFrEF | HFrEF |
| Country | United States | United States | United States | United States | United States | United States | China | China | China |
| Completion Date | 2019/7/17 | 2021/8/13 | 2019/10/07 | 2019/10/09 | 2020/03/07 | 2020/07/09 | 2020/10/31 | 2020/12/31 | 2021/04/30 |
| NCT ID | NCT03036124 | NCT03030235 | NCT03448419 | NCT03448406 | NCT03877237 | NCT03877224 | NR | NR | NR |
| Study | DAPA-HF [7, 36, 37] | DAPA-Preserved [38, 39] | EMPERIAL-Reduced [40, 41] | EMPERIAL-Preserved [40, 41] | DETERMINE-reduced [42] | DETERMINE-Preserved [43] | Zheng et al [44] | Li et al [45] | Wu et al [46] |